Boosting blood plasma-derived pharmaceutical products in India alongside cell-based therapy for treating rare diseases of metabolism MNGIE, HCU, and PKU. Rius Medical is a supplier of innovation for improved BIOLOGICs via stem cell engineering. That’s right, via bone marrow-derived hematopoietic stem cells into “cultured red blood cells inclusive enzyme cargo”, Rius Medical develops biopharmaceuticals, proteins, and peptides for treating metabolic diseases and cancer alongside 4x recombinant plasma proteins.
Startup Description
As a supplier of innovation, Rius Medical develops biopharmaceuticals, proteins and peptides for the treatment of metabolic diseases and cancer alongside recombinant plasma proteins.
To bridge the huge gap that exists between the availability of Plasma & Specialty Care products, and immense need of its therapies in India and other developing economies. Rius Medical identifies and develops partnerships on strategic business opportunities.
Product Screenshots
Business Model
Out-Licensing in Denmark and in India of "rare disease innovation" by Rius Medical that simplifies manufacture of enzyme-loaded RBCs. That is allogeneic cell therapy with a single source of cells to treat many patients. Cells are collected from a donor sample to create a master cell bank (MCB). The MCB is then used as the source to create cell populations that are processed according to the demands of the specific therapy. [It is not iPSC but bone marrow derived stem cells engineered as MCB for cultured red blood cells inclusive biologic enzyme cargo].
Customers
based in
India, Europe
Business
Modal Type
Marketplace
Type of
Sales
B2C, B2B
Competitors
* Octapharma
* CSL
* Takeda
* Grifols
Teams
Denis Demarais
Founder and Managing Director
Are all the founders full-time on this
project?
Yes
Looking for an
opportunity to invest in companies
like Enzyme Cargo?
